COPD CASE 2 ĐỢT CẤP COPD A KIỆT 17/10/2026

Summary

The video is a long, case-based teaching session on diagnosing and managing COPD exacerbations. The instructor asks students to explain why they reach a conclusion rather than simply reciting a diagnosis or treatment. The subtitles are heavily garbled, so some clinical terms and details are uncertain.

Main ideas

• Reason from symptoms to a diagnosis. Work step by step: identify symptoms, decide what syndrome they suggest, consider possible causes, then make and justify a diagnosis. Shortness of breath should not automatically be attributed to COPD; cardiac and other causes also need consideration.
• Use current COPD classification guidance. The session discusses the change from the older ABCD grouping to the ABE grouping in newer GOLD guidance. It emphasizes that exacerbation history affects group assignment and that Group E is not itself a COPD severity “stage.”
• Confirm COPD and assess airflow obstruction. Spirometry is discussed as the basis for confirming persistent airflow obstruction and grading lung-function impairment. The class also discusses changes in bronchodilator-response criteria between older and newer guidance, though the precise threshold in the subtitles is unclear.
• Choose treatment according to the patient’s features and risks. The group discusses initial and follow-up inhaled therapy, blood eosinophil levels, prior exacerbations, and possible contraindications. A history of tuberculosis or recurrent infection is raised as a reason to be cautious about inhaled corticosteroids (ICS).
• Check for complications and alternative explanations. The cases prompt discussion of respiratory infection, pneumonia, cardiac disease, arrhythmias, pulmonary embolism, and medication effects. The instructor distinguishes a COPD exacerbation with possible infection from pneumonia, which may require a different treatment approach.
• Reassess before escalating therapy. If symptoms persist, first check inhaler technique, adherence, whether the current treatment is being used correctly, and whether another condition is causing breathlessness. Medication escalation is not automatic.
• Plan beyond the acute episode. Follow-up, spirometry after recovery, smoking cessation, pulmonary rehabilitation, vaccination, and patient education are presented as important parts of COPD care.

Case-based reasoning and assessment

The session discusses two clinical cases:

• One patient is described as an older man with a history of smoking, previous pulmonary tuberculosis, a prior COPD diagnosis, and repeated hospitalizations for breathlessness. The class considers an acute COPD exacerbation associated with a lower respiratory infection and discusses classifying the patient as Group E under the newer framework.
• A later case involves several days of worsening breathlessness in a patient with established COPD and substantial smoking exposure. The students work through the history, examination, investigations, likely trigger, and severity. The transcript includes discussion of raised white blood cells and inflammatory markers, possible low potassium, and a chest X-ray without a clear new pneumonia finding; these details are difficult to verify from the subtitles.

Suggested clinical approach taught in the session

Take a focused history

• Clarify when breathlessness began, how it has changed, and what makes it better or worse.
• Ask about cough, sputum volume or colour, wheezing, fever, chest pain, coughing blood, and other associated symptoms.
• Establish smoking exposure and relevant history, including COPD, asthma, tuberculosis, previous exacerbations or admissions, current medicines, and treatment adherence.
• Consider cardiac symptoms and other causes of breathlessness rather than assuming COPD is responsible.

Examine and identify the main syndromes

• Assess respiratory rate, oxygen saturation, work of breathing, and general severity.
• Look for signs of airflow obstruction or hyperinflation, such as wheezing or an expanded chest, as well as signs of infection.
• Look for findings that could point to cardiac disease, including peripheral swelling or other signs of heart failure.
• State the findings clearly and explain how they support or weaken each possibility.

Build and test a differential diagnosis

• Consider COPD exacerbation, asthma, lower respiratory infection or pneumonia, and cardiac causes.
• Consider pulmonary embolism or other diagnoses when the history, examination, or tests suggest them.
• Use the evidence to explain why one diagnosis is more likely and what still needs to be ruled out.

Use investigations to answer specific questions

• Discussed tests include spirometry when the patient is stable, arterial blood gas analysis when indicated, blood count, electrolytes, inflammatory markers, ECG, and chest X-ray.
• Pay attention to potassium, since the session notes that beta-agonist treatment can lower it.
• Interpret imaging systematically and look for new infiltrates that would support pneumonia.
• Do not treat a possible ECG pattern or imaging clue as a definitive diagnosis without adequate supporting evidence.

Treatment points discussed

Stable COPD management

• For a patient in Group E, the session discusses dual long-acting bronchodilator therapy (LABA/LAMA) as an initial approach.
• The class considers adding ICS in selected patients, with blood eosinophils—especially the threshold discussed in the lesson—and exacerbation history informing the decision.
• Before stepping up treatment for persistent breathlessness, check the diagnosis, inhaler technique, adherence, and other possible causes.
• For ongoing exacerbations despite inhaled treatment, the discussion mentions possible further options, including triple therapy and, in selected cases, roflumilast, azithromycin, or biologic medicines. These are presented as options requiring patient-specific assessment, not as routine choices.
• The instructor highlights potential risks: ICS-related infection concerns, azithromycin-related QT prolongation and drug interactions, and gastrointestinal effects with roflumilast. The subtitles do not reliably preserve all the stated indications or drug details.

Acute exacerbation management

• Controlled oxygen: The target range discussed is SpO₂ 88–92%, with monitoring rather than giving unrestricted oxygen.
• Short-acting bronchodilators: The session discusses using a short-acting beta-agonist together with an antimuscarinic bronchodilator during an acute episode.
• Systemic corticosteroid: The instructor discusses a short course, including a regimen described in the subtitles as prednisone-equivalent treatment for five days. The exact wording is unclear.
• Antibiotics: The class considers antibiotics when the exacerbation is complicated or there is evidence suggesting bacterial infection. The instructor stresses choosing treatment according to severity and risk factors, rather than assuming every flare requires the same antibiotic.
• Treat other contributing problems: The group also considers correcting low potassium and looking for pneumonia, cardiac disease, or other causes of the patient’s symptoms.

Discharge, prevention, and follow-up

The session treats discharge planning as part of COPD care, not an afterthought. Topics discussed include:

• Reassessing symptoms and how often rescue medication is needed.
• Reviewing medication use, inhaler technique, and adherence.
• Arranging follow-up, generally around four to six weeks in the discussion, with earlier review where appropriate.
• Repeating spirometry when the patient is clinically stable rather than relying on measurements taken during a severe acute episode.
• Encouraging smoking cessation and reducing exposure to respiratory irritants.
• Considering vaccination, including influenza, pneumococcal, COVID-19, RSV, and pertussis/tetanus vaccines; exact recommendations vary by patient and current guidance.
• Offering pulmonary rehabilitation and breathing exercises, including pursed-lip and diaphragmatic breathing.

Core lesson

The instructor’s recurring teaching point is to understand the rationale behind each step. Students are encouraged to organize findings logically, explain why a treatment is chosen, check for contraindications, and avoid memorizing a plan without understanding how it applies to the individual patient.

Speakers and sources featured

• Primary speaker: An unnamed instructor or lecturer leading the case discussion.
• Named student participants: Khánh, Vi, and An. Huy and Quỳnh are also mentioned, but their roles are unclear in the subtitles.
• Sources discussed or referenced: GOLD guidance, including the 2023-era change and a 2026 update as described in the session; textbooks and course documents; teaching slides, including slides attributed to Vu; and research evidence mentioned in connection with combination inhalers and other COPD treatments. The subtitles do not provide enough reliable detail to identify every study precisely.